Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 12/20 | 0.55 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.42 |
| ▸ | ITGAV | P06756 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28832884 | 0.92 | ROCK2 (0.53) | ROCK2LMNAHTTSIRT2 | |
| SCHEMBL12330028 | 0.90 | ROCK2 (0.48) | ROCK2LMNAHTTPDE4APDE4B | |
| SCHEMBL12330029 | 0.89 | ROCK2 (0.49) | ROCK2LMNAHTTNT5EITGB3 | |
| SCHEMBL12329645 | 0.88 | ROCK2 (0.44) | ROCK2LMNAHTTNR1H4ITGB3 | |
| SCHEMBL2441309 | 0.87 | HTT (0.48) | ROCK2LMNAHTTPDE4APDE4B | |
| SCHEMBL2475618 | 0.87 | ROCK2 (0.43) | ROCK2LMNAHTTNR1H4ITGB3 | |
| SCHEMBL2442485 | 0.87 | ROCK2 (0.59) | ROCK2 | |
| SCHEMBL12330030 | 0.86 | ROCK2 (0.46) | ROCK2LMNAHTT | |
| SCHEMBL2445126 | 0.82 | ROCK2 (0.69) | ROCK2IKBKETBK1SIRT2NT5E | |
| SCHEMBL14245262 | 0.82 | ROCK2 (0.45) | ROCK2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912209-B2 | Rock inhibitors | AMAKEM NV (BE) | 2014-12-16 | — | — | US | disclosed |
| US-8912209-B2 | Rock inhibitors | AMAKEM NV (BE) | 2014-12-16 | — | — | US | disclosed |
| US-8912209-B2 | Rock inhibitors | AMAKEM NV (BE) | 2014-12-16 | — | — | US | disclosed |
| US-8815873-B2 | Heterocyclic amides as rock inhibitors | AMAKEM NV (BE) | 2014-08-26 | — | — | US | disclosed |
| US-8815873-B2 | Heterocyclic amides as rock inhibitors | AMAKEM NV (BE) | 2014-08-26 | — | — | US | disclosed |
| US-8815873-B2 | Heterocyclic amides as rock inhibitors | AMAKEM NV (BE) | 2014-08-26 | — | — | US | disclosed |
| US-20130252975-A1 | NOVEL ROCK INHIBITORS | AMAKEM NV (BE) | 2013-09-26 | — | — | US | disclosed |
| US-20130252975-A1 | NOVEL ROCK INHIBITORS | AMAKEM NV (BE) | 2013-09-26 | — | — | US | disclosed |
| US-20130252975-A1 | NOVEL ROCK INHIBITORS | AMAKEM NV (BE) | 2013-09-26 | — | — | US | disclosed |
| EP-2626348-A1 | Heterocyclic amides as rock inhibitors | Amakem NV (BE) | 2013-08-14 | — | — | EP | disclosed |
| EP-2626348-A1 | Heterocyclic amides as rock inhibitors | Amakem NV (BE) | 2013-08-14 | — | — | EP | disclosed |
| EP-2542528-B1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | AMAKEM NV (BE) | 2013-06-19 | — | — | EP | disclosed |
| EP-2542528-B1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | AMAKEM NV (BE) | 2013-06-19 | — | — | EP | disclosed |
| EP-2542528-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | Amakem NV (BE) | 2013-01-09 | — | — | EP | disclosed |
| US-20120322801-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | AMAKEM NV (BE) | 2012-12-20 | — | — | US | disclosed |
| US-20120322801-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | AMAKEM NV (BE) | 2012-12-20 | — | — | US | disclosed |
| US-20120322801-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | AMAKEM NV (BE) | 2012-12-20 | — | — | US | disclosed |
| WO-2011107608-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | AMAKEM NV (BE) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011107608-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | AMAKEM NV (BE) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322801-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | ROCK1, ROCK2, CIT | ROCK2 2/4885IKBKE 227/4885TBK1 186/4885 |
| US-20130252975-A1 | NOVEL ROCK INHIBITORS | ROCK1, ROCK2, CIT | ROCK2 2/4885IKBKE 403/4885TBK1 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.